Application of quality by design to the development of analytical separation methods

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 2-3, 2013, Pages 443-450

  Orlandini, Serena ^a   Pinzauti, Sergio ^a   Furlanetto, Sandra ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Capillary electrophoresis; Chromatography; Design of experiments; Design space; Pharmaceuticals; Quality by design

Indexed keywords

CAPILLARY ELECTROPHORESIS; CHROMATOGRAPHY; DESIGN OF EXPERIMENTS; DRUG PRODUCTS; RISK ASSESSMENT;

ANALYTICAL METHOD; ANALYTICAL SEPARATIONS; CONTROL STRATEGIES; DESIGN SPACES; METHOD DEVELOPMENT; PROCESS UNDERSTANDING; QUALITY BY DESIGNS; REGULATORY DOCUMENTS;

PRODUCT DESIGN;

EID: 84873701785     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6302-2     Document Type: Review

References (47)

1. Pharmaceutical CGMPs for the 21st century - A Risk-Based Approach. Final report (2004) US Food and Drug Administration. http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/Manufacturing/ QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM176374. pdf. Accessed 14 Jun 2012
2. Guidance for Industry. PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf. Accessed 14 Jun 2012
3. Guidance for Industry. Q8(R2) Pharmaceutical Development (2009) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073507.pdf. Accessed 14 Jun 2012
4. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8(R2) (2009) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q8-R1/Step4/Q8-R2-Guideline.pdf. Accessed 14 Jun 2012
5. ICH Harmonised Tripartite Guideline. Quality Risk Management Q9 (2005) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q9/Step4/Q9-Guideline.pdf. Accessed 14 Jun 2012
6. ICH Harmonised Tripartite Guideline. Pharmaceutical Quality Systems Q10 (2008) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q10/Step4/Q10-Guideline.pdf. Accessed 14 Jun 2012
7. S Verma Y Lan R Gokhale DJ Burgess 2009 Int J Pharm 377 185 198 10.1016/j.ijpharm.2009.05.006 1:CAS:528:DC%2BD1MXotlOlsLw%3D
8. S Adam D Suzzi C Radeke JG Khinast 2011 Eur J Pharm Sci 42 106 115 10.1016/j.ejps.2010.10.013 1:CAS:528:DC%2BC3cXhs1agtLjL
9. N Mennini S Furlanetto M Cirri P Mura 2012 Eur J Pharm Biopharm 80 67 75 10.1016/j.ejpb.2011.08.002 1:CAS:528:DC%2BC3MXhs1Cqu7jP
10. JG Rosas M Blanco JM González M Alcalá 2011 J Pharm Sci 100 4432 4441 10.1002/jps.22611 1:CAS:528:DC%2BC3MXhtVylur7O
11. H Wu M White MA Khan 2011 Int J Pharm 405 63 78 10.1016/j.ijpharm.2010. 11.045 1:CAS:528:DC%2BC3MXovVWgsg%3D%3D
12. NA Charoo AAA Shamsher AS Zidan Z Rahman 2012 Int J Pharm 423 167 178 10.1016/j.ijpharm.2011.12.024 1:CAS:528:DC%2BC38XhslCkt7w%3D
13. P Lebrun F Krier J Mantanus H Grohganz M Yang E Rozet B Boulanger B Evrard J Rantanen P Hubert 2012 Eur J Pharm Biopharm 80 226 234 10.1016/j.ejpb.2011.09.014 1:CAS:528:DC%2BC3MXhs1Cqu7vI
14. am Ende D, Bronk KS, Mustakis J, O'Connor G, Santa Maria CL, Nosal R, Watson TJN (2007) J Pharm Innov 2:71-86
15. AS Rathore 2009 Trends Biotechnol 27 546 553 10.1016/j.tibtech.2009.06. 006 1:CAS:528:DC%2BD1MXhtVeitbfI
16. S Martin-Moe FJ Lim A Sreedhara J Sundaram SU Sane 2011 J Pharm Sci 100 3031 3043 10.1002/jps.22545 1:CAS:528:DC%2BC3MXnsVCrt7k%3D
17. PF Gavin BA Olsen 2008 J Pharm Biomed Anal 46 431 444 10.1016/j.jpba.2007.10.037 1:CAS:528:DC%2BD1cXlvV2htQ%3D%3D
18. Hibbert DB (2012) Experimental design in chromatography: a tutorial review. J Chromatogr B. doi: 10.1016/j.jchromb.2012.01.020
19. G Hanrahan R Montes FA Gomez 2008 Anal Bioanal Chem 390 169 179 10.1007/s00216-007-1619-y 1:CAS:528:DC%2BD2sXhsVKgur7J
20. E Korakianiti D Rekkas 2011 Pharm Res 28 1465 1479 10.1007/s11095-010- 0315-3 1:CAS:528:DC%2BC3cXhsFKitrfN
21. FG Vogt AS Kord 2011 J Pharm Sci 100 797 812 10.1002/jps.22325 1:CAS:528:DC%2BC3MXht1Ckur0%3D
22. Piepel G, Pasquini B, Cooley S, Heredia-Langner A, Orlandini S, Furlanetto S (2012) Talanta 97:73-82
23. I Molnár HJ Rieger KE Monks 2010 J Chromatogr A 1217 3193 3200 10.1016/j.chroma.2010.02.001
24. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1) (2005) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/ Q2-R1/Step4/Q2-R1-Guideline.pdf. Accessed 14 Jun 2012
25. M McBrien 2010 Chromatogr Today 3 30 34
26. B Debrus P Lebrun A Ceccato G Caliaro E Rozet I Nistor R Oprean FJ Rupérez C Barbas B Boulanger P Hubert 2011 Anal Chim Acta 691 33 42 10.1016/j.aca.2011.02.035 1:CAS:528:DC%2BC3MXkt1Gms70%3D
27. P Debrus P Lebrun J Mbinze Kindenge F Lecomte A Ceccato G Caliaro J Mavar Tayey Mbay B Boulanger RD Marini E Rozet P Hubert 2011 J. Chromatogr A 1218 5205 5215 10.1016/j.chroma.2011.05.102 1:CAS:528:DC%2BC3MXptVOlu7o%3D
28. RA Lionberger SL Lee LM Lee A Raw LX Yu 2008 AAPS J 10 268 276 10.1208/s12248-008-9026-7 1:CAS:528:DC%2BD1cXhtlOgsbvP
29. P Borman P Nethercote M Chatfield D Thompson K Truman 2007 Pharm Tech 31 142 152
30. Ishikawa K (1985) What is total quality control? The Japanese Way. Prentice-Hall, Englewood Cliffs, pp 63-64
31. KE Monks H-J Rieger I Molnár 2011 J Pharm Biomed Anal 56 874 879 10.1016/j.jpba.2011.04.015 1:CAS:528:DC%2BC3MXhtF2rurvO
32. J Huang G Kaul C Cai R Chatlapalli P Harnandez-Abad K Ghosh A Nagi 2009 Int J Pharm 382 23 32 10.1016/j.ijpharm.2009.07.031 1:CAS:528:DC%2BD1MXhtlSlur7N
33. M Swartz IS Krull J Turpin PH Lukulay R Verseput 2009 LC GC Am 27 328 339
34. S Furlanetto S Orlandini I Giannini G Beretta S Pinzauti 2009 Electrophoresis 30 633 643 10.1002/elps.200800626 1:CAS:528:DC%2BD1MXjsFKjurc%3D
35. D Awotwe-Otoo C Agarabi PJ Faustino MJ Habib S Lee MA Khan RB Shah 2012 J Pharm Biomed Anal 62 61 67 10.1016/j.jpba.2012.01.002 1:CAS:528: DC%2BC38Xis1eiurs%3D
36. I Molnár KE Monks 2011 Chromatographia 73 S5 S14 10.1007/s10337-011-1968-8
37. I Krull M Swartz J Turpin PH Lukulay R Verseput 2008 LC GC Am 26 1190 1197
38. I Krull M Swartz J Turpin PH Lukulay R Verseput 2009 LC GC Am 27 48 61
39. Cornell JA (2002) Experiments with mixtures, 3rd edn. John Wiley & Sons, New York
40. I Giannini S Orlandini R Gotti S Pinzauti S Furlanetto 2009 Talanta 80 781 788 10.1016/j.talanta.2009.07.071 1:CAS:528:DC%2BD1MXht1yltLrI
41. S Orlandini I Giannini M Villar Navarro S Pinzauti S Furlanetto 2010 Electrophoresis 31 3296 3304 10.1002/elps.201000066 1:CAS:528:DC%2BC3cXhsVWqu7fN
42. S Orlandini R Gotti I Giannini B Pasquini S Furlanetto 2011 J Chromatogr A 1218 2611 2617 10.1016/j.chroma.2011.02.062 1:CAS:528:DC%2BC3MXkvFWrtb8%3D
43. S Furlanetto M Cirri G Piepel N Mennini P Mura 2011 J Pharm Biomed Anal 55 610 617 10.1016/j.jpba.2011.01.008 1:CAS:528:DC%2BC3MXlsFant7o%3D
44. G Derringer R Suich 1980 J Qual Technol 12 214 219
45. P Lebrun B Govaerts B Debrus A Ceccato G Caliaro P Hubert B Boulanger 2008 Chemom Intell Lab Syst 91 4 16 10.1016/j.chemolab.2007.05.010 1:CAS:528:DC%2BD1cXislGntLg%3D
46. B De Backer B Debrus P Lebrun L Theunis N Dubois L Decock A Verstraete P Hubert C Charlier 2009 J Chromatogr B 877 4115 4124 10.1016/j.jchromb.2009.11. 004
47. K Monks I Molnár H-J Rieger B Bogáti E Szabó 2012 J Chromatogr A 1232 218 230 10.1016/j.chroma.2011.12.041 1:CAS:528: DC%2BC38XjsFKmt7s%3D